Insulin degludec news archive

Take a look back at Novo Nordisk company announcements and press releases on developments for insulin degludec and insulin degludec / insulin aspart.

31 August 2012
Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan

20 April 2012
Two phase 3 studies on ultra-long-acting insulin degludec published today in The Lancet

9 March 2012
Novo Nordisk files for regulatory approval of the co-formulation insulin degludec/insulin aspart in Japan

26 September 2011
Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe

14 September 2011
Data show that ultra-long-acting insulin degludec can be flexibly dosed at any time of the day in people with type 2 diabetes

27 June 2011
Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control in patients with type 1 and type 2 diabetes

Insulin degludec is an ultra-long-acting basal insulin being developed by Novo Nordisk. Insulin degludec and insulin degludec / insulin aspart have been submitted to regulatory authorities for review but have not yet been approved for use.

APROM ID# 4045. Date of Approval: May 2012